Report
Louis AZAIS

Analyse court terme - BIOMERIEUX : Plus haut historique

La tendance est toujours haussière, son niveau d'invalidation est sous 75,50 €. L'objectif est à 84,60 €.

Arguments :
- Le support majeur est atteint, il cause le rebond.
- La résistance a été dépassée, mais elle est réintégrée. Les prix peuvent baisser.
- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.
- La moyenne mobile sert de support.
Underlying
BioMerieux SA

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis AZAIS

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch